Definition and epidemiology
Frontotemporal dementia (FTD) refers to a clinically and pathologically heterogeneous group of neurodegenerative conditions caused by frontotemporal lobar degeneration (FTLD). It is the clinical syndrome; FTLD is the underlying pathology.
- Second or third most common cause of dementia in patients under 65, after early-onset Alzheimer disease.
- Peak onset 45-65 years; mean age of onset roughly 58.
- Accounts for a meaningful minority of young-onset dementia cases in memory clinic cohorts.
- Roughly 20-40% of cases have a family history; about 10-15% show autosomal dominant inheritance.
- Prevalence is likely underestimated due to frequent misdiagnosis as a primary psychiatric disorder.
- FTD typically presents at 45-65 years, younger than typical Alzheimer disease onset.
- Behavioral variant FTD features early personality change and disinhibition with relatively preserved memory.
- C9orf72 repeat expansion is the most common known genetic cause and links FTD to ALS.
- MRI shows frontal and/or anterior temporal atrophy; FDG-PET shows frontal/temporal hypometabolism.
- Cholinesterase inhibitors and memantine are not effective in FTD and may worsen behavior.
- SSRIs are first-line pharmacologic treatment for behavioral symptoms.
- Semantic variant PPA causes loss of word meaning; nonfluent variant causes agrammatic, effortful speech.
- Pick bodies are a classic tau pathology finding in some FTLD cases.
Etiology and risk factors
FTD arises from progressive neuronal loss in the frontal and anterior temporal lobes, driven by abnormal protein aggregation.
Genetics
- MAPT (microtubule-associated protein tau) mutations
- GRN (granulin) mutations, often with TDP-43 pathology
- C9orf72 hexanucleotide repeat expansion — most common known genetic cause, also linked to ALS (FTD-ALS overlap)
- Family history is the strongest identifiable risk factor; a positive family history should prompt genetic counseling and testing.
Molecular pathology
- FTLD-tau: includes Pick disease (Pick bodies), corticobasal degeneration, progressive supranuclear palsy
- FTLD-TDP: TDP-43 inclusions, often linked to GRN or C9orf72
- FTLD-FUS: rarer, fused-in-sarcome protein inclusions
No consistently proven environmental risk factor exists; a prior history of traumatic brain injury has been proposed but evidence is weaker than for CTE.
Pathophysiology
Selective degeneration of the frontal and anterior/medial temporal cortices disrupts circuits governing social behavior, executive function, emotional regulation, and language.
- Orbitofrontal and anterior cingulate involvement drives disinhibition, apathy, and loss of empathy.
- Dorsolateral prefrontal involvement impairs executive function and planning.
- Anterior temporal and left perisylvian involvement produces the language variants (semantic and nonfluent/agrammatic primary progressive aphasia).
- Hippocampal and parietal regions are relatively spared early, which explains why episodic memory and visuospatial function remain intact until later stages — a key point of distinction from Alzheimer disease.
- Overlap with motor neuron disease occurs because TDP-43 pathology and C9orf72 mutations are shared with ALS.
Clinical features
FTD clinical syndromes are divided into behavioral and language variants.
Behavioral variant FTD (bvFTD) — most common
- Progressive personality and behavioral change: disinhibition, apathy, loss of empathy/sympathy
- Perseverative, stereotyped, or compulsive behaviors
- Hyperorality and dietary changes (overeating, sweet food cravings)
- Poor insight; relatively preserved memory and visuospatial skills early
- Executive dysfunction (poor planning, impaired judgment)
Primary progressive aphasia variants
- Semantic variant: loss of word meaning, impaired naming and single-word comprehension, fluent but empty speech
- Nonfluent/agrammatic variant: effortful, agrammatic speech with apraxia of speech
Associated/overlap syndromes
- FTD-ALS overlap: upper and lower motor neuron signs (fasciculations, weakness, bulbar symptoms)
- Corticobasal syndrome and progressive supranuclear palsy–like presentations with parkinsonism
Diagnosis
Diagnosis is primarily clinical, supported by neuropsychological testing, imaging, and in select cases genetic/CSF biomarkers.
- Neuropsychological testing: disproportionate executive and behavioral dysfunction relative to memory; frontal-type deficits on tests like the Frontal Assessment Battery
- MRI brain: frontal and/or anterior temporal atrophy, often asymmetric; knife-blade atrophy pattern in advanced disease
- FDG-PET: frontal and/or anterior temporal hypometabolism, helps distinguish from Alzheimer disease (which shows parietotemporal hypometabolism)
- CSF biomarkers / amyloid PET: used to help exclude Alzheimer disease when the picture is ambiguous
- Genetic testing: offered when family history suggests autosomal dominant inheritance (MAPT, GRN, C9orf72)
- Diagnostic criteria (e.g., Rascovsky criteria for bvFTD) require at least three of six core features: disinhibition, apathy/inertia, loss of empathy, perseverative/compulsive behavior, hyperorality, and dysexecutive neuropsychological profile.
Differential diagnosis
| Condition | Distinguishing feature |
|---|---|
| Alzheimer disease | Early prominent episodic memory loss, parietotemporal atrophy/hypometabolism |
| Primary psychiatric disorder (depression, bipolar, schizophrenia-like psychosis) | Often considered first due to behavioral onset; lacks progressive atrophy on imaging |
| Dementia with Lewy bodies | Visual hallucinations, parkinsonism, fluctuating cognition, REM sleep behavior disorder |
| Vascular dementia | Stepwise decline, vascular risk factors, infarcts on imaging |
| Progressive supranuclear palsy / corticobasal degeneration | Prominent parkinsonism, vertical gaze palsy, apraxia, alien limb |
| Amyotrophic lateral sclerosis (isolated) | Pure motor neuron signs without behavioral change (though overlap exists) |
Management
There is no disease-modifying or curative therapy for FTD; management is supportive and symptomatic, following consensus from major neurology and dementia societies (AAN, EAN, Alzheimer's Association guidance on dementia care).
Pharmacologic
- SSRIs (e.g., sertraline, citalopram) — first-line for behavioral symptoms such as disinhibition, compulsions, and irritability
- Trazodone — may help with agitation and sleep disturbance
- Atypical antipsychotics — used cautiously and sparingly for severe agitation/aggression when non-pharmacologic measures fail, given increased cerebrovascular and mortality risk in dementia patients
- Cholinesterase inhibitors and memantine (used in Alzheimer disease) are not effective and may worsen behavioral symptoms in FTD — an important distinction for exams
Non-pharmacologic
- Caregiver education and support; FTD caregiver burden is high due to behavioral symptoms and younger patient age
- Speech and language therapy for PPA variants
- Occupational therapy, structured routines, environmental safety modification
- Multidisciplinary care involving neurology, psychiatry, social work, and palliative care as disease progresses
- Genetic counseling for families with identified mutations
Complications and prognosis
FTD is relentlessly progressive, with a shorter overall survival than typical late-onset Alzheimer disease.
- Median survival from symptom onset is approximately 6-8 years, though this varies by subtype and presence of ALS overlap (worse prognosis with motor neuron involvement).
- Progressive loss of independence, worsening behavioral disturbance, and eventual mutism/immobility in advanced stages.
- Increased caregiver burden and psychiatric misdiagnosis delay appropriate care.
- Aspiration pneumonia and other complications of advanced immobility are common terminal events.
FTD mnemonic — 'DELTA' for bvFTD core features: Disinhibition, Empathy loss, Loss of initiative (apathy), Taste changes (hyperorality), Apathy/dysexecutive behavior.
Practice questions
1. A 58-year-old man is brought in by his wife, who reports that over the past year he has become rude to coworkers, started shoplifting small items without concern, and now eats excessive amounts of sweets. He scores normally on a memory recall test but performs poorly on tests of executive function. MRI shows atrophy of the frontal and anterior temporal lobes. Which of the following is the most likely diagnosis?
2. A 61-year-old woman presents with progressive difficulty finding words and understanding the meaning of common objects, though her speech remains fluent and grammatically correct. Her brother was diagnosed with a similar condition in his 50s. Genetic testing in the family reveals a hexanucleotide repeat expansion. Which gene is most likely involved?
3. A 55-year-old man with a diagnosis of behavioral variant frontotemporal dementia is started on donepezil by a physician who assumed the same treatment approach as Alzheimer disease. Two weeks later, his family reports worsening agitation and disinhibition. What is the most appropriate next step in management?
Frequently asked questions
What causes frontotemporal dementia?
FTD is caused by progressive degeneration of the frontal and temporal lobes due to abnormal buildup of tau, TDP-43, or FUS proteins in neurons. About 20-40% of cases run in families, with genes like MAPT, GRN, and C9orf72 identified. In most sporadic cases, the exact trigger for protein misfolding is unknown.
What are the first symptoms of frontotemporal dementia?
The earliest symptoms are usually personality and behavior changes rather than memory loss, such as disinhibition, apathy, loss of empathy, or socially inappropriate behavior. Some patients instead first develop language problems, like difficulty finding words or understanding word meaning. Family members often notice the change before the patient does, since insight is typically impaired.
How is frontotemporal dementia diagnosed?
Diagnosis relies on a detailed clinical history from family, neuropsychological testing showing executive/behavioral deficits with relatively preserved memory, and brain MRI or FDG-PET showing frontal and/or anterior temporal atrophy or hypometabolism. Genetic testing and CSF or PET amyloid biomarkers may be used to rule out Alzheimer disease. No single test confirms FTD; it is a clinical diagnosis supported by imaging.
Is frontotemporal dementia curable?
No, frontotemporal dementia is not curable and there is currently no treatment that slows or reverses the underlying neurodegeneration. Management focuses on controlling behavioral symptoms with medications like SSRIs, providing speech therapy for language variants, and supporting caregivers. Research into disease-modifying therapies targeting tau and TDP-43 is ongoing but not yet approved.
Frontotemporal dementia vs Alzheimer disease — what is the difference?
FTD typically starts earlier (45-65 years), begins with personality or language changes, and spares memory early, while Alzheimer disease usually starts later and begins with prominent short-term memory loss. Imaging differs too: FTD shows frontal/temporal atrophy, while Alzheimer shows parietotemporal and hippocampal involvement. Cholinesterase inhibitors help Alzheimer disease but are not effective, and may worsen symptoms, in FTD.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: G31.0
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.